Vimizim

Drug - Vimizim™ (elosulfase) [BioMarin Pharmaceuticals Inc.]

November 2014

Therapeutic area - Metabolic disease enzyme replacement

Approval criteria

• Patient is 5 years of age or older AND
• Patient has a diagnosis of Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome)

Quantity limit

• Dosing will be limited to 2 mg/kg/week. Approval will include a quantity sufficient for a 34-day supply. Patient’s weight in kilograms must be supplied at time of prior authorization request and for any subsequent dose increases.

Questions?

MHCP Provider Call Center 651-431-2700 or 800-366-5411